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Abstract
Four  new  phenylethanoid  glycosides  (1-4),  1-β-p-hydroxyphenyl-ethyl-2-O-acetyl-3,6-di-α-L-
rhamnopyranosyl-β-D-glucopyranoside (1),  1-β-p-hydroxyphenyl-ethyl-3,6-O-di-α-L-
rhamnopyranosyl-β-D-glucopyranoside (2),  1-β-p-hydroxyphenyl-ethyl-2-O-acetyl-3,6-di-α-L-
rhamnopyranosyl-4-p-coumaroyl-β-D-glucopyranoside (3),  and  1-β-p-hydroxyphenyl-ethyl-3,6-di-
α-L-rhamnopyranosyl-4-p-coumaroyl-β-D-glucopyranoside (4),  together  with  three  known
compounds,  were  isolated  from the  n-butanol  extract  of  Cistanche  phelypaea aerial  parts.  The
structural characterization of all compounds was performed by spectroscopic analyses, including 1D
and  2D  NMR,  and  HRESIMS  experiments.  The  isolated  compounds were  assayed  for  their
inhibitory activity on two enzymes involved in the peculiar  glycolytic or lipidic metabolism of
cancer  cells,  human  lactate  dehydrogenase  (LDH)  and  monoacylglycerol  lipase  (MAGL),
respectively.  All  the  compounds  showed  negligible  activity  on  LDH,  whereas  some  of  them
displayed a certain inhibition activity on MAGL. In particular, compound 1 was the most active on
MAGL showing an IC50 = 88.0 µM and modeling studies rationalized the supposed binding mode of
1 in the MAGL active site.
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Introduction
Cistanche is a genus of Orobanchaceae family including about 20 species, usually  holoparasitic
desert plants, that lack chlorophyll and obtain their nutrients and water from the roots of host plants
that they parasitize. This genus is distributed to certain arid and semi-arid regions of Africa, Asia
and Mediterranean area, including parts of Southern Europe [1]. Some Cistanche species are used
for food application and in the traditional Chinese medicine as tonic for the treatment of kidney
deficiency, impotence, infertility, profuse metrorrhagia, and chronic constipation [2]. The secondary
metabolites  produced  by  the  representatives  of  the Cistanche genus  include  phenylethanoid
glycosides, lignans, iridoids, and oligosaccharides [3-5] some of which have been shown to possess
interesting biological  activity such  as anti-inflammatory,  neuroprotective,  immunomodulatory,
antioxidative,  antibacterial,  and antiviral  properties  [2].  Cistanche phelypaea (L.)  Coutinho syn.
Cistanche tinctoria (Desf.) Beck is an erect perennial parasite plant, with numerous yellow flowers
and absent roots: the plant  attaches itself to its host (Tamarix gallica,  Calligonum comosum and
Pulicaria  sp.)  through  small  tubers.  In  the  North  Africa  traditional  medicine,  it  is  used  for
diarrhoea,  diabetes,  intestinal  troubles,  infection, and as a diuretic [6]. Previous chemical  study
revealed the presence of iridoids and phenylethanoids as main constituents [7,8]. 
As a part of our research program for characterization of the biological activity of different classes
of natural products [9,10], herein, we report the isolation and the structure characterization of four
new  phenylethanoid  glycosides  (1-4)  (Fig.  1),  along  with  three  known  compounds  from  C.
phelypaea aerial  parts.  The  isolates  were  assayed  for  their  lactate  dehydrogenase  (LDH)  and
monoacylglycerol  lipase  (MAGL)  inhibitory  activity.  In  fact,  tumor  cells  exhibit  progressive
metabolic  changes  that  are  correlated  with  malignancy.  In  particular,  glycolytic  and  lipidic
pathways are reprogrammed in order to support the rapid growth of proliferating cells [11]. These
dysregulated metabolic pathways are typical features of cancer and, at the same time, they may
offer therapeutic windows for anticancer agents that target them. In this context, LDH and MAGL
are two enzymes overexpressed in tumor tissues, which play key roles in the typical glycolytic and
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lipidic cancer metabolism, respectively [12,13]. In particular, the human isoform 5 of the enzyme
lactate dehydrogenase (hLDH5), made of four A subunits, catalyzes the final step of glycolysis,
which consists in the reduction of pyruvate to lactate, thus allowing the ATP production in cancer
cells that rely on glycolysis for their survival. Glycolytic cancer cells display high glucose uptake
and  elevated  lactate  production,  and  the  overexpression  of  specific  enzymes  such  as  LDH  is
necessary to assure a sufficient energy production. Therefore, the inhibition of this crucial enzyme
may be considered as  a  promising strategy to counteract  cancer  invasiveness,  without affecting
normal cells, which instead use oxidative phosphorylation for most of their purposes. On the other
hand, MAGL is a serine hydrolase that cleaves monoacyglycerols into fatty acids and glycerol. In
particular,  MAGL is the lipolytic enzyme that  is  mainly responsible for the degradation of the
endocannabinoid  2-arachidonoylglycerol  (2-AG),  which  is  a  neurotransmitter  and  an  important
intermediate  in  lipid  metabolism  involved  in  many  physiological  processes.  Moreover,  the
intensified production of fatty acids in cancer  cells,  generated by MAGL activity, increases the
formation of pro-tumorigenic signalling molecules  [14]. Therefore, MAGL represents a potential
target to treat diverse pathological conditions, including cancer. In the last decades, a great effort
has been directed towards the identification of small molecules that are able to inhibit LDH [15,16]
or MAGL  [17,18] and many compounds displaying efficient  inhibitory activity on these targets
were  either  discovered  from natural  sources  or  obtained  by  chemical  synthesis.  Therefore,  the
search for LDH or MAGL inhibitors represents an attractive goal to find new effective anticancer
drugs interfering with the peculiar cancer metabolism and, therefore, has prompted us to carry out
the investigation herein reported.
Results and discussion
The  phytochemical  study  of  C.  phelypaea n-butanol  extract,  after  submission  to  flash  column
chromatography followed by RP-HPLC, afforded four new phenylethanoid glycosides (1-4) (Fig. 1)
and three known compounds, named brandioside  [19], pinoresinol 4-O-β-D-glucopyranoside  [20],
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and apigenin 7-O-β-glucuronopyranoside  [21] by comparison of  NMR and MS data with those
reported in the literature.
Compound 1 was obtained as a brownish amorphous solid with a molecular formula C28H42O16, as
determined by  13C NMR and HRESIMS analyses (m/z 657.2353 [M+Na]+). The positive ESIMS
spectrum  showed  a  sodiated  molecular  ion peak at  m/z 657  [M+Na]+,  while  its  fragmentation
pattern  was  characterized  by  peaks  at  m/z 597 [M+Na−60]+,  511  [M+Na−146]+,  and  365
[M+Na−146−146]+,  due to  the subsequent  loss  of  an  acetyl  group  and two deoxyhexose  units,
respectively. The 1H NMR spectra of 1 (Table 1) exhibited characteristic signals of ortho-coupled
A2B2 type aromatic  protons at  δ 6.71 (2H, d,  J  = 8.0 Hz) and 7.04 (2H, d,  J  = 8.0 Hz),  three
anomeric protons at δ 4.44 (1H, d, J = 8.0 Hz), 4.76 (1H, d, J = 1.3 Hz), and 4.80 (1H, d, J = 1.5
Hz), an acetyl group at δ 2.00 (3H, s), two methyl groups at δ 1.26 (3H, d, J = 6.3 Hz) and 1.27 (3H,
d,  J = 6.5 Hz),  and two methylenes at δ 4.04 (1H, m), 3.62 (1H, m), and 2.80 (2H, m). These
evidences  suggested the presence  of  a  phenylethanol  residue and three sugar  moieties  [5].  The
observation of 13C NMR spectrum (Table 1) confirmed these findings. The structures of the sugar
units were assigned by 1D TOCSY and 2D NMR experiments, indicating the presence of one  β-
glucopyranoside and two α-rhamnopyranosyl residues. The complete assignments of all protons and
carbons were based by the analysis of HSQC, COSY, and HMBC data,  indicating that the two
rhamnopyranosyl units were terminal units. The relative configuration of the anomeric carbon of the
glucose residue was deduced to be  β from the coupling constant  (J  = 8.0 Hz) of the anomeric
proton.  In  the  case  of  the  rhamnose  residue,  the  α anomeric  configuration  was  derived  by
comparison of the pertinent 13C NMR data with those reported in literature [9]. The configuration of
the  sugar  units  was  assigned  after  hydrolysis  of  1  with  1  N  HCl.  The  hydrolyzate  was
trimethylsilylated,  and GC retention times of each sugar were compared with those of authentic
samples prepared in the same manner. The HMBC spectrum of 1 displayed the correlations between
the proton signal at  δH 4.44 (H-1glc) and carbon  resonance at δC 72.5 (C-8), confirming that the
phenylethanol moiety was linked to C-1glc. Similarly, the correlation between signals at δH 4.78 (H-
2glc) and  δC 171.3 suggested  that the acetyl group was linked to C-2glc. Likewise,  the long range
correlations between δH 4.76 (H-1rhaI) and carbon resonance δC 83.1 (C-3glc), δH 4.80 (H-1rhaII) and δC
68.0 (C-6glc), allowed to establish that the two α-L-rhamnopyranosyl moieties were linked at C-3glc
and C-6glc, respectively. Thus, the structure of 1 was established as 1-β-p-hydroxyphenyl-ethyl-2-O-
acetyl-3,6-di-α-L-rhamnopyranosyl-β-D-glucopyranoside.
The molecular  formula  of  compound  2,  isolated as  a  brownish amorphous  solid,  was assigned
C26H40O15, as deduced by HRESIMS analyses (m/z 615.2232 [M+Na]+), as well as from 13C NMR
data. The ESIMS/MS spectrum displayed two fragments at m/z 469 [M+Na−146]+ and 323 [M+Na
–146−146]+ attributable to the subsequent loss of two deoxyhexose units, respectively. Comparison
of 1H and 13C NMR spectra of 2 (Table 1) with those of 1 revealed 2 to differ from 1 only for the
absence of the acetyl group at C-2 of glucose unit. Thus, the structure of 2 was determined as 1-β-p-
hydroxyphenyl-ethyl-3,6-O-di-α-L-rhamnopyranosyl-β-D-glucopyranoside. 
Compound 3 displayed a molecular formula C37H48O18 by HRESIMS (m/z 803.2715 [M+Na]+). The
ESIMS of 3 showed a sodiated molecular ion peak at m/z 803 [M+Na]+ and a fragmentation pattern
with peaks at m/z 743 [M+Na−60]+, 657 [M+Na−146]+, and 511 [M+Na–146−146]+, corresponding
to the subsequent loss of an acetyl moiety and two deoxyhexose units. Analysis of NMR data of 3
(Table 1), besides chemical shifts similar to those of  1, displayed the presence of two couples of
signals attributable to trans-olefinic protons at δ 6.37 (1H, d, J = 16.0 Hz, H-αtrans) and 7.70 (1H, d,
J = 16.0 Hz, H-βtrans), cis-olefinic protons at δ 5.83 (1H, d, J = 12.0 Hz, H-αcis) and 6.97 (1H, d, J =
12.0 Hz, H-βcis), and two couples of ortho-coupled A2B2 aromatic protons at δ 6.84 (2H, d, J = 8.0
Hz, H-3/H-5trans) and 7.44 (2H, d, J = 8.0 Hz, H-2/H-6trans), and 6.80 (2H, d, J = 8.0 Hz, H-3/H-5cis)
and 7.75 (2H, d, J = 8.0 Hz, H-2/H-6cis). Also in this case the assignments of all proton and carbon
signals were deduced from a combined analysis of 1D and 2D NMR experiments. Moreover, key
correlation peaks in  the HMBC spectrum of 3 between the proton signal at  δH 5.12 (H-4glc) and
carbon  resonance  at δC 168.0  (COO),  δH 4.88  (H-2glc)  and  δC 171.6  (COCH3),  were  present,
confirming that the p-coumaroyl group was linked to C-4glc while the acetyl group at C-2glc.  Thus,
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compound 3 was identified as an inseparable mixture 7:3 of 1-β-p-hydroxyphenyl-ethyl-2-O-acetyl-
3,6-di-α-L-rhamnopyranosyl-4-trans-p-coumaroyl-β-D-glucopyranoside (3a)  and  1-β-p-
hydroxyphenyl-ethyl-2-O-acetyl-3,6-di-α-L-rhamnopyranosyl-4-cis-p-coumaroyl-β-D-
glucopyranoside (3b). 
The HRESIMS of compound 4, a brownish amorphous solid, showed a sodiated molecular ion peak
at  m/z 761.2604 [M+Na]+, corresponding to the molecular formula C35H46O17. In  the ESIMS/MS
fragmentation  pattern  of  m/z 761  [M+Na]+,  peaks  at  m/z 615 [M+Na−146]+ and  469  [M+Na–
146−146]+,  due  to  the  subsequent  loss  of  two  deoxyhexose  units,  respectively,  were  evident.
Comparison of NMR data of  4 (Table 1) with those of  3 showed in  4 the absence of the acetyl
group at C-2glc. In the light of these data, compound 4 was established to be an inseparable mixture
7:3  of  1-β-p-hydroxyphenyl-ethyl-3,6-di-α-L-rhamnopyranosyl-4-trans-p-coumaroyl-β-D-
glucopyranoside (4a)  and  1-β-p-hydroxyphenyl-ethyl-3,6-di-α-L-rhamnopyranosyl-4-cis-p-
coumaroyl-β-D-glucopyranoside (4b).
Phenylethanoids  1-4, pinoresinol  4-O-β-D-glucopyranoside,  brandioside,  and  apigenin  7-O-β-
glucuronopyranoside were assayed on human LDH5 and MAGL purified isoforms to determine
their inhibition potencies (Table 2).  All the compounds were inactive on  hLDH5, showing IC50
values greater than 200  µM, thus being less potent than reference compound galloflavin  [22]. In
hMAGL  enzymatic  assays,  only  two  derivatives  (compound  4 and  apigenin  7-O-β-
glucuronopyranoside)  proved  to  be  inactive,  whereas  pinoresinol  4-O-β-D-glucopyranoside  and
brandioside exhibited IC50 values of 130.2 and 156.1 µM, respectively. Compounds 2 and 3 showed
a better inhibition activity, with similar IC50 values of 117.4 and 113.9 µM, respectively. The best
inhibition potency on  hMAGL was demonstrated by compound  1, with an IC50 value in the low
micromolar range (88.0 µM), and it proved to be selective for  hMAGL over  hLDH. Although its
inhibition  activity  was  lower  than  reference  MAGL  synthetic  inhibitor  (4-(4-
chlorobenzoyl)piperidin-1-yl)(4-methoxyphenyl)-methanone (compound “CL6a” [17]), this natural
compound is the first phenylethanoid, bearing β-D-glucopyranosyl and α-L-rhamnopyranosyl sugar
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units, displaying a promising activity on  hMAGL. Presently, only few compounds derived from
natural  sources have shown an inhibitory activity on this enzyme  [23], however  they belong to
different chemical classes. 
In order to better characterize the binding mode of compound 1 into MAGL, its complex with the
target  protein  was  subjected  to  docking  calculations.  In  particular,  the  putative  binding  pose
emerging from these modeling studies showed that  the sugar  moiety lies in the wide lipophilic
cavity of the protein forming lipophilic interactions with L148, L213, L241, and V183, whereas the
p-hydroxyphenyl-ethyl  ring  lies  into  the  small  pocket  of  the  binding  site  and  forms  lipophilic
interactions  with  residues  Y194 and  V270 (Fig.  2).  A high  number  of  H-bonds  stabilizes  the
binding  disposition  of  compound  1:  the  carbonyl  group  of  the  O-acetyl  group  linked  to  the
glucopyranoside forms two H-bonds with the backbone nitrogen of A51 and M123 and the 4-OH of
the 3-α-L-rhamnopyranoside forms an H-bond with the oxygen backbone of L241. Compound 1 is
also  characterized  by  an  intramolecular  H-bond  between  the  ethereal  oxygen  of  the  6-α-L-
rhamnopyranoside  and  the  4-OH  of  the  same  portion.  Furthermore,  the  OH  group  of  the  p-
hydroxyphenyl-ethyl portion forms an H-bond with residue E53, in which it behaves as a H-bond
donor.
In summary, seven compounds, including four new structures (1-4) were isolated and characterized
from the aerial parts of  Cistanche phelypaea. The isolation and structural characterization of  the
new  phenylethanoids  1-4 and  the known  compound  pinoresinol  4-O-β-D-glucopyranoside,  are
completely  in  agreement  with  the  available  information  on  the  chemical  types  of  secondary
metabolites  typical of Cistanche  species  [24,25],  while  brandioside  and  apigenin  7-O-β-
glucuronopyranoside,  are  reported  from  this  genus  for  the  first  time  here.  Moreover,  to  our
knowledge this is the first report of naturally occurring phenyletanoid as  a MAGL inhibitor. This
study will open the way for future investigation on plant glycosylated small molecules as potential
MAGL inhibitors.
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Materials and Methods
General experimental procedures
Optical rotations were measured on an Atago AP-300 digital polarimeter equipped with a sodium
lamp (589 nm) and a 1 dm microcell. NMR experiments were recorded at 300 K in CD3OD on a
Bruker  DRX-600  spectrometer  (Bruker  BioSpin  GmBH)  equipped  with  a  Bruker  5  mm  TCI
CryoProbe as reported previously  [26].  HRESIMS were acquired in the positive ion mode on a
LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific).  ESIMS were obtained from an
LCQ  Advantage  ThermoFinnigan  spectrometer  (ThermoFinnigan),  equipped  with  a  Xcalibur
software. Column chromatography was performed over Sephadex LH-20 (40-70 µm, Pharmacia) at
a flow rate 0.8 mL/min. HPLC separations were conducted on a Shimadzu LC-8A series pumping
system equipped with a Shimadzu RID-10A refractive index detector and Shimadzu injector on a
C18 µ-Bondapak column (30 cm x 7.8 mm, 10 µm Waters, flow rate 2.0 mL/min). TLC analyses
were carried  out using glass-coated silica gel  60 F254 (0.20 mm thickness)  plates  (Merck)  with
CHCl3-MeOH-H2O (70:30:3)  as  eluent  and cerium sulphate  as  spray reagent. GC analysis  was
performed using a Dani GC 1000 instrument on a  L-CP-Chirasil-Val column (0.32 mm  ×  25 m)
working with the following temperature program: 100 °C for 1 min, ramp of 5 °C/min up to 180 °C;
injector and detector temperature 200 °C; carrier gas N2 (2.0 mL/min); detector dual FID; split ratio
1:30; injection 5 µL.
Plant material 
Cistanche phelypaea aerial parts were collected in March 2012 in the South West of Algeria.  The
plant was identified by Prof. Gérard De Bélair, Faculty of Sciences, University of Annaba, Algeria.
A voucher specimen (number Ct.03.12) has been deposited in the Herbarium of the Department of
Chemistry, Université des Frères Mentouri-Constantine, Constantine, Algeria.
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Extraction and isolation
The dried and powdered aerial parts (4 kg) of C. phelypeae were extracted with MeOH-H2O (4:1) at
room temperature for 48 h. The extraction was repeated three times by changing the solvent. The
obtained  extract was  filtered,  concentrated,  and  successively  extracted  with  petroleum  ether,
chloroform, ethyl acetate and  n-butanol, to give 3.27, 4.87, 10.96, and 36.86 g of the respective
residues. The n-butanol extract (10.59 g) was subjected to column chromatography over Sephadex
LH-20 in MeOH. Fractions of 12 mL were collected, analyzed by TLC and grouped to give eleven
major fractions (A-K). Fraction K contained pure apigenin 7-O-β-D-glucuronopyranoside (28 mg).
Fraction B (245.1 mg) was purified by RP-HPLC with MeOH-H2O (3:7) as eluent to obtain pure
compound 1 (7.9 mg,  tR 21 min). Fraction C (896.8 mg) was purified by RP-HPLC with MeOH-
H2O (25:75) as eluent to afford pure compound 2 (6.3 mg, tR 15 min). Fraction E (638.9 mg) was
purified by RP-HPLC with MeOH-H2O (45:55) as eluent to give brandioside (7 mg, tR 15 min) and
compounds 4 (14.9 mg, tR 20 min) and 3 (11.1 mg, tR 34 min). Fraction G (172.6 mg) was purified
by RP-HPLC with MeOH-H2O (35:65) as eluent to obtain pinoresinol 4-O-β-D-glucopyranoside
(3.6 mg, tR 18 min).
Compound 1: brownish amorphous solid;  -58.5 (c 0.1, MeOH); UV (MeOH) λmax (log ε): 223
(4.20), 280 (3.50), 321 (3.06); 1H and 13C NMR data, see Table 1; ESIMS m/z 657 [M+Na]+, 597
[M+Na−60]+, 511 [M+Na−146]+, 451 [M+Na−60−146]+, 365 [M+Na−146−146]+; HRESIMS: m/z
657.2353 [M+Na]+ (calcd. for C28H42NaO16, m/z 657.2371). 
Compound 2: brownish amorphous solid;  -7.0 (c 0.1, MeOH); UV (MeOH) λmax (log ε): 222
(4.09), 280 (3.55), 315 (3.10); 1H and 13C NMR data, see Table 1; ESIMS m/z 615 [M+Na]+, 469
[M+Na−146]+, 323 [M+Na−146−146]+; HRESIMS: m/z 615.2232 [M+Na]+ (calcd. for C26H40NaO15,
m/z 615.2265).
Compound 3: brownish amorphous solid;  -96 (c 0.1, MeOH); UV (MeOH) λmax (log ε): 225
(4.26), 316 (3.87); 1H and 13C NMR data, see Table 1; ESIMS m/z 803 [M+Na]+, 743 [M+Na−60]+,
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657  [M+Na−146]+,  511  [M+Na−146−146]+;  HRESIMS:  m/z 803.2715  [M+Na]+  (calcd.  for
C37H48NaO18, m/z 803.2738).
Compound 4: brownish amorphous solid;  -85.5 (c 0.1, MeOH); UV (MeOH) λmax (log ε): 224
(4.30),  315  (3.85);  1H  and  13C  NMR  data,  see  Table  1; ESIMS  m/z 761  [M+Na]+,  615
[M+Na−146]+, 469 [M+Na−146−146]+; HRESIMS: m/z 761.2604 [M+Na]+ (calcd. for C35H46NaO17,
m/z 761.2633).
Acid hydrolysis of compounds 1-4
A solution of each compound (2.0 mg) in 1 N HCl (1 mL) was stirred at 80 °C in a stoppered
reaction vial for 4 h. After cooling, the solution was evaporated under a stream of N2. The residue
was dissolved in 1-(trimethylsilyl)imidazole and pyridine (0.2 mL, 1:1), and the solution was stirred
at 60 °C for 5 min. After drying the solution, the residue was partitioned between H2O and CHCl3.
The  CHCl3 layer  was  analyzed  by  GC using a  L-CP-Chirasil-Val  column (0.32  mm x  25 m).
Temperatures of both the injector and detector was 200 °C. A temperature gradient system was used
for the oven, starting at 100 °C for 1 min and increasing up to 180 °C at a rate of 5 °C/min. Peaks of
the hydrolysate were detected by comparison with retention times of authentic samples of D-glucose
and L-rhamnose (Sigma Aldrich) after treatment with 1-(trimethylsilyl)imidazole in pyridine.
Enzymatic assays
All  the compounds were  assayed  against  purified  hLDH5 (Lee  Biosolution,  Inc.)  and  hMAGL
(Cayman Chemical), as previously reported [15,17]. The reference MAGL synthetic inhibitor (4-(4-
chlorobenzoyl)piperidin-1-yl)(4-methoxyphenyl)-methanone (compound “CL6a”) was synthesized
in our laboratory (purity percentage 99% by HPLC analysis),  as previously reported [17]. Both
assays  were  performed  in  96-well  plates  at  room  temperature  at  a  final  volume  of  200  µL.
Compounds were dissolved in DMSO stock solutions at the maximum concentration of 625 µM
(the concentration of DMSO did not exceed 4% during the measurements), and this solution was
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diluted to seven different concentrations (from 625 to 0.86 µM, in duplicate for each concentration)
that were used to generate the concentration-response curve.  All the IC50 values are the mean of
three independent experiments. Maximum and minimum controls were also included in each plate.
The enzymatic  reaction for LDH assays was performed in the “forward” direction (pyruvate  to
lactate), and the amount of consumed NADH was monitored (340 nm). Assays were performed in
100 mM phosphate buffer (pH = 7.4), in the presence of 200 µM pyruvate and 40 µM NADH. After
15 min of incubation, the final measurements were carried out by using a Victor X3 microplate
reader (PerkinElmer). IC50 values were derived from experimental data using the sigmoidal dose-
response fitting of GraphPad Prism software. The enzymatic reaction for MAGL assays was based
on the conversion of the substrate 4-nitrophenylacetate (4-NPA) to 4-nitrophenol and the amount of
produced  4-nitrophenol  was  monitored  (405  nm),  as  previously  reported  [27].  Assays  were
performed in 10 mM Tris buffer (pH = 7.2), containing 1 mM EDTA and 0.1 mg/mL BSA, in the
presence of 100 µM 4-NPA. After the reaction had proceeded for 30 min, absorbance values were
then measured by using a Victor X3 microplate reader (PerkinElmer).  IC50 values were derived
from experimental data using the sigmoidal dose-response fitting of GraphPad Prism software.
Docking studies
The crystal structure of  hMAGL (pdb code 3PE6  [28]) was sourced from the Protein Data Bank
[29]. First we added hydrogen atoms, then the protein complexed with its reference inhibitor was
minimized using Amber14 software [30] and ff14SB force field at 300 K. The complex was placed
in a rectangular parallelepiped water box, an explicit solvent model for water (TIP3P) was used, and
the  complex  was  solvated  with  a  10  Å  water  cap.  To  neutralize  the  system,  sodium ions  as
counterions were added, then two steps of minimization were carried out: firstly, the protein was
kept  fixed  with  a  position  restraint  of  500  kcal/mol·Å2  and  only  the  positions  of  the  water
molecules  were minimized.  Secondly,  the entire  system through 5000 steps  of  steepest  descent
followed by a conjugate gradient (CG) was minimized, until a convergence of 0.05 kcal/Å·mol was
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reached. The ligands were built using Maestro [31] and minimized by means of Macromodel [32] in
a water environment, following the CG method to obtain a convergence value of 0.05 kcal/Å·mol,
using  the  MMFF’s  force  field  and  a  distance-dependent  dielectric  constant  of  1.0.  Automated
docking was carried out by means of the AUTODOCK 4.0 program [33]; Autodock Tools [34] was
used to identify the torsion angles in the ligands, add the solvent model, and assign the Kollman
atomic charges to the protein. The ligand charge was calculated using the Gasteiger method. By
considering the ZYH reference inhibitor as  the central  group, the regions of interest  used were
defined by Autodock; in particular a grid of 82, 40, and 30 points in the x, y, and z directions,
centered  on  the  core  of  the  mass  of  this  compound,  was  constructed.  For  the  energetic  map
calculations a grid spacing of 0.375 Å and a distance-dependent function of the dielectric constant
were  used.  With  the  aid  of  the  Lamarckian  Genetic  Algorithm,  the  docked  compounds  were
subjected to 100 runs of the Autodock search, using 500000 steps of energy evaluation and the
default values of the other parameters. The cluster analysis on the results was performed using an
RMS tolerance of 2.0 Å.
Supporting information
HRESIMS and NMR spectra of compounds 1-4 and data for the IC50 determination of compound 1
in MAGL enzymatic assays are available as Supporting Information.
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Legends for Figures
Fig. 1 Chemical structures of compounds 1-4 isolated from C. phelypaea (L.) aerial parts.
Fig.  2. View  of  the  most  relevant  ligand−receptor  interactions  of  the  1−hMAGL  complex.
Hydrogen bonds are represented as black dashed lines.
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Table 1 1H and 13C-NMR data of compounds 1-4 (CD3OD, 600 MHz, J in Hz)
position 1 2 3a/3b 4a/4b
δH δC δH δC δH δC δH δC
1 131.0 131.0 131.7 130.7
2/6 7.04 d (8.0) 131.2 7.07 d (8.0) 131.5 7.05 d (8.0) 131.3 7.10 d (8.0) 130.9
3/5 6.71 d (8.0) 116.3 6.72 d (8.0) 116.4 6.73 d (8.0) 116.2 6.73 d (8.0) 116.2
4 157.0 157.1 157.0 157.1
7 2.80 m 36.4 2.85 m 37.6 2.78 m 36.0 2.86 m 36.7
8a 4.04 m 72.5 3.99 m 72.0 4.06 m 72.3 4.02 m 72.7
8b 3.62 m 3.74 m 3.65 m 3.75 m
glc-1 4.44 d (8.0) 103.2 4.34 d (7.8) 104.6 4.55 d (7.8) 102.1 4.40 d (8.0) 104.6
2 4.78 dd (9.0, 8.0) 75.0 3.29 dd (9.5, 7.8) 75.0 4.88 dd (9.5, 7.8) 74.3 3.40 dd (9.5, 8.0) 76.4
3 3.65 t (9.0) 83.1 3.50 t (9.5) 83.8 4.03 t (9.5) 80.8 3.83 t (9.5) 81.9
4 3.44 t (9.0) 70.1 3.35a 70.0 5.12 t (9.5) 69.3 5.00 t (9.5) 70.2
5 3.46 m 77.1 3.43 m 76.3 3.77 m 75.2 3.70 m 74.9
6a 4.00 dd (12.0, 3.0) 68.0 3.99 dd (12.0, 3.0) 68.0 3.79 dd (12.0, 3.0) 67.5 3.77 dd (12.0, 3.5) 67.8
6b 3.68 dd (12.0, 4.5) 3.65 dd (12.0, 5.0) 3.50 dd (12.0, 5.0) 3.49 dd (12.0, 4.5)
COCH3 171.3 171.6
COCH3 2.00 s 21.2 1.98 s 21.4
rhaI-1 4.76 d (1.3) 102.1 5.21 d (2.0) 100.8 4.77 d (1.8) 103.3 5.21 d (2.0) 102.7
2 3.83 dd (3.0, 1.8) 72.8 3.96 dd (3.0, 2.0) 71.6 3.74 dd (3.0, 1.8) 71.7 3.94 dd (3.0, 2.0) 72.4
3 3.96 dd (9.0, 3.0) 72.0 3.70 dd (9.0, 3.0) 70.7 3.54 dd (9.0, 3.0) 72.0 3.60 dd (9.0, 3.0) 72.7
4 3.39 t (9.0) 74.3 3.39 t (9.0) 73.4 3.29 t (9.0) 73.0 3.31 t (9.0) 74.2
5 3.68 m 70.7 3.69 m 71.2 3.54 m 70.2 3.58 m 70.6
6 1.26 d (6.3) 18.1 1.26 d (6.5) 18.3 1.08 d (6.5) 18.7 1.09 d (6.0) 18.3
rhaII-1 4.80 d (1.5) 102.5 4.76 d (1.8) 101.6 4.63 d (2.0) 102.5 4.65 d (2.0) 101.1
2 3.83 dd (3.0, 1.8) 72.6 3.85 dd (3.5, 1.8) 71.5 3.89 dd (3.5, 2.0) 71.4 3.86 dd (3.5, 2.0) 72.3
3 3.96 dd (9.0, 3.0) 72.4 3.70 dd (9.0, 3.5) 72.3 3.70 dd (9.0, 3.5) 72.0 3.75 dd (9.0, 3.5) 72.6
4 3.39 t (9.0) 74.0 3.40 t (9.0) 74.0 3.37 t (9.0) 73.2 3.34a 74.0
5 3.68 m 70.6 3.99 m 70.0 3.64 m 69.3 3.66 m 70.7
6 1.27 d (6.5) 18.3 1.27 d (6.5) 18.1 1.22 d (6.0) 18.3 1.21 d (6.0) 18.5
p-coum-1 127.3 127.4
2/6 trans 7.44 d (8.0) 131.3 7.50 d (7.8) 130.9
2/6 cis 7.75 d (8.0) 134.6 7.72 d (7.8) 133.4
3/5 trans 6.84 d (8.0) 116.2 6.83 d (7.8) 116.2
3/5 cis 6.80 d (8.0) 115.3 6.80 d (7.8) 115.2
4 162.0 161.7
α-trans 6.37 d (16.0) 114.9 6.38 d (16.0) 114.0
α-cis 5.83 d (12.0) 115.9 5.83 d (12.0) 115.2
β-trans 7.70 d (16.0) 148.1 7.71 d (16.0) 147.3
β-cis 6.97 d (12.0) 147.7 6.99 d (12.0) 146.4
COO 168.0 168.0
J values are in parentheses and reported in Hz; chemical shifts are given in ppm; assignments were
confirmed by COSY, 1D-TOCSY, HSQC, and HMBC experiments. Glc =  β-D-glucopyranoside,
rha = α-L-rhamnopyranosyl, p-coum = p-coumaroyl. a Overlapped signal.
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Table 2 hLDH5 and hMAGL inhibition potencies
compound
IC50 (µM)
hLDH5 CI (95%, n = 3) hMAGL CI (95%, n = 3)
1 > 200 - 88.0 [60.7, 127.6]
2 > 200 - 117.4 [95.0, 145.1]
3a/3b > 200 - 113.9 [93.8, 138.4]
4a/4b > 200 - > 200 -
pinoresinol 4-O-β-D-glucopyranoside > 200 - 130.2 [110.2, 153.8]
brandioside > 200 - 156.1 [151.1, 164.7]
apigenin 7-O-β-glucuronopyranoside > 200 - > 200 -
galloflavin 110.1 [82.9, 146.2] -a -
CL6a -a - 12.1 [8.9, 16.3]
a Not tested.
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